POLICY and PROCEDURE MANUAL Facility-Based Registry Edition

Total Page:16

File Type:pdf, Size:1020Kb

POLICY and PROCEDURE MANUAL Facility-Based Registry Edition WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES West Virginia Cancer Registry 2 0 0 7 POLICY AND PROCEDURE MANUAL Facility-Based Registry Edition Bureau for Public Health 350 Capitol Street, Room 125 Charleston, WV 25301 Joe Manchin III, Governor Martha Yeager Walker, Secretary 2007 Policy and Procedure Manual Facility-Based Registry Edition Joe Manchin III Governor Martha Yeager Walker Secretary, Department of Health and Human Resources Chris Curtis, MPH Acting Commissioner, Bureau for Public Health Catherine Slemp, MD, MPH Acting State Health Officer, Bureau for Public Health Joe Barker, MPA Director, Office of Epidemiology and Health Promotion Loretta Haddy, PhD Director, Division of Surveillance and Disease Control Patricia Colsher, PhD Director/Epidemiologist, West Virginia Cancer Registry Cover images courtesy of the National Cancer Institute Visuals Online. Top left: Medulloblastoma. Top right: Ependymoma. Lower left: Oligodendroglioma. Lower right: Glioblastoma. Manual Prepared and Cover Design, Graphics and Layout by: Patricia Colsher, PhD Director/Epidemiologist, West Virginia Cancer Registry Materials Reviewed by: Darlene Maxwell, CTR Leslie Boner, CTR Lee Ann Phalen, CTR WVCR Data Quality Staff WVCR Staff Patricia Colsher, PhD Director/Epidemiologist Darlene Maxwell, CTR Data Quality/Training Leslie Boner, CTR Data Quality/Training Lee Ann Phalen, CTR Data Quality/Training R. Neal Kerley, CTR Systems Management Brenda Shehab Surveillance Stephen Williams Surveillance Judy Arbogast Surveillance Jena Webb Support Services CHAPTER 5: CASE ASCERTAINMENT Table of Resources 20 General Guidelines 20 Contents Screening Lists of ICD-9 Codes 21 Other Sources to Review 23 CHAPTER 1: THE WEST CHAPTER 6: VIRGINIA CANCER ABSTRACTING OVERVIEW REGISTRY Resources 25 Mission 1 Introduction to Abstracting 26 Geographic Coverage 1 Temporal Coverage 2 CHAPTER 7: Confidentiality 2 ABSTRACTING: GENERAL ISSUES Release of Identified Information 2 Text Documentation 60 Funding 3 Ambiguous Terminology 62 Certification 3 Descriptive Tumor Size 64 Use of WVCR Data 3 CHAPTER 8: CHAPTER 2: HEALTH ABSTRACTING: PATIENT INSURANCE PROTABILITY IDENTIFICATION AND ACCOUNTABILITY Name 65 ACT Social Security Number 66 Permissibility of Reporting 4 Address 67 West Virginia HIPAA Resources 4 Telephone 69 Other HIPAA Resources 5 Marital Status 70 County at Diagnosis 71 CHAPTER 3: REPORTING REQUIREMENTS Age at Diagnosis 72 Reportable Diseases 6 Place of Birth 73 Computerized Edits 9 Date of Birth 74 Timeliness 9 Occupation and Industry 75 Data Format 9 Census Tract & Associated Items 76 Method of Reporting 10 Race 77 Spanish/Hispanic Origin 80 CHAPTER 4: REQUIRED IHS Link 82 DATA ELEMENTS Computed Ethnicity & Source 83 Determination 11 Sex 84 Summary of Required Items 12 Tobacco History 85 Alcohol History 86 iii Family History of Cancer 87 Positive Regional Nodes 187 Regional Nodes Examined 189 CHAPTER 9: ABSTRACTING: CANCER Sites of Distant Metastases 191 IDENTIFICATION Tumor Marker 1 192 Date of Diagnosis 88 Tumor Marker 2 193 Primary Site 92 Tumor Marker 3 195 Laterality 95 Summary Staging 196 Number of Primaries 1/1/93 to 12/31/06 99 Collaborative Staging 211 Number of Primaries 1/1/07 forward 122 CS Tumor Size 215 Ambiguous Termonology MP/H 130 CS Extension 220 Date Conclusive Termonology MP/H 134 CS Tumor Size/Extension Evaluation 221 Multiplicity Counter MP/H 135 CS Lymph Nodes 223 Date Multiple Tumors MP/H 138 CS Nodes Positive 226 Type of Multiple Tumors MP/H 140 CS Nodes Examined 228 ICD-O-3 Histologic Type 142 CS Lymph Node Evaluation 230 Behavior Code 149 CS Metastases at Diagnosis 231 Grade 151 CS Mets at Diagnosis Evaluation 233 Diagnostic Confirmation 162 CS Site Specific Factor 1 235 CS Site Specific Factor 2 238 CHAPTER 10: ABSTRACTING: CS Site Specific Factor 3 240 REPORTING SOURCE CS Site Specific Factor 4 242 Reporting Source 165 CS Site Specific Factor 5 244 Place of Diagnosis 167 CS Site Specific Factor 6 246 Primary Payer 168 Coding None vs. Unknown 248 Physicians 171 Abstracted by 173 CHAPTER 12: Accession Year 174 ABSTRACTING: Abstract Number 175 TREATMENT Sequence Number 176 Introduction 250 Date First Contact 178 First Course of Therapy 251 Medical Record Number 179 Date Therapy Initiated 259 Class of Case 180 Surgery of Primary Site 262 Surgical Margins 264 Scope of Regional Lymph Node Surgery 265 CHAPTER 11: Surgical Procedure of Other Site 267 ABSTRACTING: STAGING Reason No Surgery 268 Introduction 182 Radiation 270 Tumor Size 184 Radiation Sequence with Surgery 275 Descriptive Equivalents of Size 186 iv APPENDIX E Reason No Radiation 277 USPS ZIP Codes 349 Chemotherapy 278 Hormone Therapy 282 APPENDIX F Immunotherapy 285 FIPS Codes for West Virginia 376 Hematologic / Endocrine 289 Palliative Procedure 293 APPENDIX G Other Therapy 294 Race and Nationality Descriptions 378 Systemic/Surgery Sequence 299 APPENDIX H SEER Geocodes 390 CHAPTER 13: ABSTRACTING: APPENDIX I OUTCOMES Customizing the Newest CS Manual 407 Date of Last Contact 301 Vital Status 303 APPENDIX J Autopsy 304 Head & Neck SSF 414 Cause/Underlying Cause of Death 305 Colon, Rectosigmoid and Rectum SSF 420 Place of Death 306 Liver SSF 421 Pleura SSF 423 Melanoma SSF 424 CHAPTER 14: QUALITY CONTROL Mycosis Fungoides SSF 427 Faciloty Activities 307 Breast SSF 428 WVCR Activities 308 Ovary SSF 435 Placenta SSF 436 CHAPTER 15: NEW FOR Prostate SSF 437 CASES DIAGNOSED IN 2007 Testis SSF 450 Changes 309 Retinoblastoma SSF 455 Brain SSF 458 APPENDIX A Thyroid SSF 459 West Virginia Code and Rule 310 Kaposi Sarcoma SSF 460 Lymphoma SSF 461 APPENDIX B USDHHS and NAACCR HIPAA Materials 316 APPENDIX C West Virginia Hospitals 323 APPENDIX D USPS Abbreviations 328 v Chapter 1 The West Virginia Cancer Registry Chapter 16-5A-2a of the The West Virginia Cancer Registry (WVCR) was established by the West Virginia West Virginia Code and Department of Health and Human Resources in 1991 as a breast and cervical cancer Title 64, West Virginia registry. In 1993, WVCR became an all-site registry, collecting data on all cancers Administrative Rules, except basal and squamous cell carcinoma of the skin and in situ cervical cancer. In Division of Health, Cancer 2002, 2 years prior to the Federal mandate, WVCR began collecting data on non- Registry, Series 68, which provide the legal basis for malignant brain and other central nervous system tumors. WVCR is funded by both WVCR, appear in State and Federal funding, with the latter administered through a cooperative Appendix A. agreement with the Centers for Disease Control and Prevention’s National Program of Cancer Registries. Mission The West Virginia Cancer Registry will collect and analyze cancer data to determine incidence rates by anatomical site, sex, race, geographic location, and other factors and monitor trends in cancer incidence and among West Virginia residents. Geographic Coverage The West Virginia Cancer Registry collects information on all cancers diagnosed and/or treated in the state of West Virginia and, through lawful reciprocal data sharing agreements, all cancers diagnosed and/or treated among West Virginia 1 residents by health care providers outside the state of West Virginia. A resident is a person reporting a West Virginia address at the time of diagnosis. Temporal Coverage The West Virginia Cancer Registry’s reference date (the start date after which reportable cancer cases must be included in the registry ) is January 1, 1993 for all cancer sites. The reference date for benign brain and CNS neoplasms is January 1, 2002. Confidentiality All West Virginia Cancer Registry employees sign a confidentiality pledge that meets the requirements of applicable state laws as well as the requirements of the Health Insurance Portability and Accountability Act (HIPAA). West Virginia code protects the confidentiality of both patient and health care provider. Legal analysis of the applicable state laws concerning the establishment and operation of the West Virginia Cancer Registry found that the West Virginia laws were, with one exception (specification of de-identification methodology), more stringent than HIPAA (http://www.wvdhhr.org/hipaa/documents/pre_matrix.pdf, pages 17 and 18 of the PDF). Release of Identified Information West Virginia code permits release of identified data only under two circumstances: 1. Data provided by a facility or reporter may be provided back to that facility or reporter as a failsafe in the event of catastrophic data loss. However, ONLY data provided by the facility or reporter may be provided. Additional information provided by other sources may NOT be disclosed. 2. When a lawful reciprocal data sharing agreement exists, WVCR may provide identified data about another state or territory’s residents or tribal entity’s members diagnosed and/or treated in West Virginia back to the state/territory/tribal entity, which, in turn, is to provide WVCR with identified data on West Virginia residents. 2 Funding The West Virginia Cancer Registry is funded by appropriations made by the State of West Virginia and by the Centers for Disease Control and Prevention’s National Program of Cancer Registries (NPCR). Additional information about the National Program of Cancer Registries is available from the CDC website at http://www.cdc.gov/cancer/npcr/about.htm. Certification The West Virginia Cancer Registry is subject to certification by the North American Association of Central Cancer Registries (NAACCR). Certification is based on timeliness, completeness and data quality. WVCR was certified at the “silver”
Recommended publications
  • Dissertation Stefan Heinmüller FINAL
    TECHNISCHE UNIVERSITÄT MÜNCHEN Institut für Allgemeinmedizin (Direktor: Univ.-Prof. Dr. Antonius Schneider) Inhalte, Qualität und Ergebnisse von randomisierten kontrollierten Studien der universitären Allgemeinmedizin in Deutschland – ein systematischer Review von 2000 bis 2014 Stefan Philipp Heinmüller Vollständiger Abdruck der von der Fakultät für Medizin der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Medizin genehmigten Dissertation. Vorsitzender: Univ.-Prof. Dr. Jürgen Schlegel Prüfer der Dissertation: 1. apl. Prof. Dr. Klaus Linde 2. Univ.-Prof. Dr. Antonius Schneider Die Dissertation wurde am 08.02.2017 bei der Technischen Universität München eingereicht und durch die Fakultät für Medizin am 21.02.2018 angenommen. Meinen Großeltern Erika und Dr. Werner Heinmüller aus Mansbach Inhaltsverzeichnis 1 Einleitung und Zielsetzung ........................................................................................ 1 1.1 Bedeutung der Hausarztmedizin ....................................................................... 1 1.2 Notwendigkeit der Forschung in der Allgemeinmedizin sowie deren universitärer Anbindung ..................................................................................... 2 1.3 Historische Entwicklung der akademischen Allgemeinmedizin in Deutschland ......................................................................................................... 3 1.4 Herausforderungen der universitären Allgemeinmedizin ............................... 5 2 Methodik ....................................................................................................................
    [Show full text]
  • Atopic, Contact, and Stasis Dermatitis
    9/2/2017 Atopic, Contact, and Stasis Dermatitis Atopic, Contact, and Stasis Dermatitis Debra Sibbald, BScPhm, ACPR, MA (Adult Education), PhD (Education) Date of Revision: February 2017 Introduction Dermatitis is a nonspecific term describing both acute and chronic skin reactions with corresponding clinical patterns and history. Although the word eczema (boiling over) has been used synonymously with atopic dermatitis, most dermatologists use the term dermatitis to describe an acute, nonspecific skin reaction that exhibits swelling, erythema, scaling, vesicles and crusts. Atopic dermatitis is a chronic inflammatory skin disease caused by mucocutaneous barrier dysfunction. Contact dermatitis is an inflammatory skin reaction caused by exposure to allergens or irritants. Stasis dermatitis is inflammation of the skin of the lower legs caused by chronic venous insufficiency. Skin changes in dermatitis reflect the pattern of inflammatory response. The appearance is similar in all forms of dermatitis, regardless of cause. When the reaction is acute, the earliest and mildest changes are erythema (redness) caused by engorgement and dilatation of the small blood vessels and, usually, swelling (edema) resulting from leakage of fluid from blood vessels and accumulation in tissues. If swelling is severe, skin cells form vesicles that fill with edema fluid; this process is called vesiculation or blistering. Breakage of blisters results in oozing or weeping and evaporation of this fluid causes crusting and scaling. Dermatitis may progress to a chronic
    [Show full text]
  • Section Ii: General Abstracting Instructions
    SECTION II: GENERAL ABSTRACTING INSTRUCTIONS 60 SECTION II: GENERAL ABSTRACTING INSTRUCTIONS It is the responsibility of every abstractor to know the content of the FCDS Data Acquisition Manual (DAM) and to update it upon receipt of any change from FCDS. Should you need training in cancer registry data collection, please visit the FCDS Learning Management System and consider taking the FCDS Abstracting Basics Course to gain a better understanding of the skills and training required to meet FCDS abstracting requirements and the national standards used when abstracting and coding cancer cases. This manual is intended to explain in detail each data item required for Florida Cancer Data System (FCDS) case reporting. It should be used as the primary information resource for any data item that must be coded and documented in accordance with Florida cancer reporting rules and statutes. Descriptions are only intended to provide sufficient detail to achieve consensus in submitting the required data. In no way does this manual imply any restriction on the type or degree of detail information collected, classified or studied within any healthcare facility-based cancer registry. Special Use Fields are available as needed. Basic Rules: 1) Always refer to the FCDS Data Acquisition Manual when completing an abstract. 2) Always submit a separate abstract for each reportable primary neoplasm identified. 3) Use leading zeros when necessary to right justify. 4) Text is required to adequately justify ALL coded values and to document supplemental information such as patient and family history of malignancy. Data items MUST be well documented in text field(s); specifically, Place of Diagnosis, Physical Exam, X-rays and Scans, Scopes and Diagnostic Tools, Surgical Procedures and Findings, Laboratory and Pathology (including: Dates of Specimen Collection, Primary Site, Histology, Behavior and Grade), and the Collaborative Stage data items including both core items and site specific factors.
    [Show full text]
  • Cancer Basics for the Caregiver It Is Common to Make Many Assumptions When You Hear the Word “Cancer.” Cancer Is Not One Disease, but Rather a Family of Diseases
    Caregiver’s Guide Types of Caregiving Caregiving can range from 24/7 hands-on assistance to driving someone to appointments to long-distance caregiving. Every situation is different. Your loved one has cancer and you want to help. At first, it all seems overwhelming. Everything that you took for granted is suddenly uncertain. Many caregivers are naturally worried about the person with cancer, and also worried about the rest of life—taking care of other family members, paying the bills, maintaining the house, and so much more. It’s important to realize two things: 1) You’re not alone— many other people have been in this situation before, and 2) there are resources available to help. We’ve prepared this booklet to guide and assist you. Much depends on the needs of the patient, your What’s essential is to understand that the role of the relationship with the patient, and practical matters loved one is to support and comfort, not to “fix” the such as where you live. problem. Every caregiving situation has the potential to be both When people are diagnosed with cancer, they don’t rewarding and stressful—often at the same time. want their loved ones to say, “I promise you that you’ll be cured.” In addition to worrying about your loved one’s cancer, you may be running the household, struggling What they want to hear is, “I love you and I’ll be here with piles of incomprehensible insurance forms, with you for whatever comes.” communicating with far-flung family members, and trying to earn enough money to pay the mounting bills.
    [Show full text]
  • Human Anatomy As Related to Tumor Formation Book Four
    SEER Program Self Instructional Manual for Cancer Registrars Human Anatomy as Related to Tumor Formation Book Four Second Edition U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutesof Health SEER PROGRAM SELF-INSTRUCTIONAL MANUAL FOR CANCER REGISTRARS Book 4 - Human Anatomy as Related to Tumor Formation Second Edition Prepared by: SEER Program Cancer Statistics Branch National Cancer Institute Editor in Chief: Evelyn M. Shambaugh, M.A., CTR Cancer Statistics Branch National Cancer Institute Assisted by Self-Instructional Manual Committee: Dr. Robert F. Ryan, Emeritus Professor of Surgery Tulane University School of Medicine New Orleans, Louisiana Mildred A. Weiss Los Angeles, California Mary A. Kruse Bethesda, Maryland Jean Cicero, ART, CTR Health Data Systems Professional Services Riverdale, Maryland Pat Kenny Medical Illustrator for Division of Research Services National Institutes of Health CONTENTS BOOK 4: HUMAN ANATOMY AS RELATED TO TUMOR FORMATION Page Section A--Objectives and Content of Book 4 ............................... 1 Section B--Terms Used to Indicate Body Location and Position .................. 5 Section C--The Integumentary System ..................................... 19 Section D--The Lymphatic System ....................................... 51 Section E--The Cardiovascular System ..................................... 97 Section F--The Respiratory System ....................................... 129 Section G--The Digestive System ......................................... 163 Section
    [Show full text]
  • Complementary Medicine the Evidence So
    Complementary Medicine The Evidence So Far A documentation of our clinically relevant research 1993 - 2010 (Last updated: January 2011) Complementary Medicine Peninsula Medical School Universities of Exeter & Plymouth 25 Victoria Park Road Exeter EX2 4NT Websites: http://sites.pcmd.ac.uk/compmed/ http://www.interscience.wiley.com/journal/fact E-mail: [email protected] Tel: +44 (0) 1392 424989 Fax: +44 (0) 1392 427562 2 PC2/Report/DeptBrochure/Evidence17 14/02/2011 3 Contents 1 Introduction................................................................................................................11 1.1 Background and history of Complementary Medicine...............................................................11 1.2 Aims.................................................................................................................................................11 1.3 Research topics................................................................................................................................11 1.4 Research tools..................................................................................................................................11 1.5 Background on the possibility of closure in May 2011..............................................................12 2 The use of complementary medicine (CM)..............................................................13 2.1 General populations........................................................................................................................13
    [Show full text]
  • Welcome to the Cancer Resource Center!
    Welcome to the Cancer Resource Center! We understand that this is a difficult time for you and your family. We are here to offer assistance throughout your diagnosis, treatment, recovery, and beyond. The welcome folder describes some of the services and support we provide to individuals and families affected by cancer. Please don’t hesitate to contact us if you have questions about any information contained in this folder. Our staff is happy to talk with you one-on-one to answer questions and to provide information and resources available both locally and nationally. We meet with couples and families as well and we always respect the confidentiality of everyone we meet with. We share information only when given permission to do so. CRC has a lending library of books and other materials that covers a wide range of cancer-related topics as well as a boutique featuring free wigs, hats, scarves, and other items that can be useful during some types of treatment. Our many support groups for individuals with cancer and their loved ones play an important role in providing assistance and connection to others with similar experiences. Our Financial Advocacy program can help provide assistance with financial concerns if needed. Our website (www.crcfl.net) includes many additional resources that may be of assistance to you and your family. We encourage you to visit it. If you do not have a computer, we will be happy to assist you in finding cancer-related information that we can mail to you. Our staff and volunteers are here to help you in any way we can.
    [Show full text]
  • Collaborative Stage Manual Part II
    SEER Program Coding and Staging Manual 2004, Revision 1 Collaborative Staging Codes Nasal Cavity C30.0 C30.0 Nasal cavity (excludes nose, NOS C76.0) Note: Laterality must be coded for this site, except subsites Nasal cartilage and Nasal septum, for which laterality is coded 0. CS Tumor Size CS Site-Specific Factor 1 - Size of The following tables are available CS Extension Lymph Nodes at the collaborative staging CS TS/Ext-Eval CS Site-Specific Factor 2 - website: CS Lymph Nodes Extracapsular Extension, Lymph Nodes Histology Exclusion Table CS Reg Nodes Eval for Head and Neck AJCC Stage Reg LN Pos CS Site-Specific Factor 3 - Levels I- Lymph Nodes Size Table Reg LN Exam III, Lymph Nodes for Head and Neck CS Mets at DX CS Site-Specific Factor 4 - Levels IV- CS Mets Eval V and Retropharyngeal Lymph Nodes for Head and Neck CS Site-Specific Factor 5 - Levels VI- VII and Facial Lymph Nodes for Head and Neck CS Site-Specific Factor 6 - Parapharyngeal, Parotid, Preauricular, and Sub-Occipital Lymph Nodes, Lymph Nodes for Head and Neck Nasal Cavity CS Tumor Size SEE STANDARD TABLE Nasal Cavity CS Extension Code Description TNM SS77 SS2000 00 In situ; non-invasive Tis IS IS 10 Invasive tumor confined to site of origin T1 L L Meatus (superior, middle, inferior) Nasal chonchae (superior, middle, inferior) Septum Tympanic membrane 30 Localized, NOS T1 L L 40 Extending to adjacent connective tissue within the nasoethomoidal T2 RE RE complex Nasolacrimal duct 60 Adjacent organs/structures including: T3 RE RE Bone of skull Choana Frontal sinus Hard palate
    [Show full text]
  • 1 2 3 4 5 6 7 8 9 10 11 12 13 1 Presidential Advisory Committee
    Presidential Advisory Committee 1 Department of Health and Human Services Centers for Disease Control and Prevention (CDC) National Institute for Occupational Safety and Health 1 (NIOSH) Advisory Board on Radiation and Worker Health 2 3 4 VOLUME I 5 6 7 The verbatim transcript of the Meeting of the Advisory Board on Radiation and Worker Health 8 held at the Washington Court Hotel, 525 New Jersey Avenue, N.W., Washington, D.C., on May 2 and 3, 9 2002. 10 NANCY LEE & ASSOCIATES Certified Verbatim Reporters P.O. Box 451196 11 Atlanta, Georgia 31145-9196 (404) 315-8305 12 13 C O N T E N T S 2 Vol. I Registration and Welcome Dr. Paul Ziemer, Chair 1 Mr. Larry Elliott, Executive Secretary. .8 Welcome and Opening Remarks Dr. Kathleen Rest, NIOSH . .11 2 Review and Approval of Draft Minutes Dr. Paul Ziemer, Chair. 18 3 Program Status Report Mr. Larry Elliott, Executive Secretary . .36 Changes to Probability of Causation Rule 4 (42 CFR Part 82) Mr. Ted Katz, NIOSH . 70 NCI-IREP 5 Dr. Charles Land, NCI . 82 NIOSH-IREP in use by DOL Dr. Mary Schubauer-Berigan, NIOSH . .115 6 Mr. Russ Henshaw, NIOSH . .176 Topics for Future Discussion Dr. Paul Ziemer, Chair . 193 7 Public Comment . 207 Discussion of Changes in the Rule . .216 8 Adjourn . .223 9 10 11 12 13 C O N T E N T S 3 Vol. II Registration and Welcome Dr. Paul Ziemer, Chair Mr. Larry Elliott, Executive Secretary . 227 1 Administrative Housekeeping Ms. Cori Homer, NIOSH . .227 2 Discussion of Rules.
    [Show full text]
  • Nr 25/20 - 2020.06.15 NO Årgang 110 ISSN 1503-4925
    . nr 25/20 - 2020.06.15 NO årgang 110 ISSN 1503-4925 Norsk varemerketidende er en publikasjon som inneholder kunngjøringer innenfor varemerkeområdet BESØKSADRESSE Sandakerveien 64 POSTADRESSE Postboks 4863 Nydalen 0422 Oslo E-POST [email protected] TELEFON +47 22 38 73 00 8.00-15.45 innholdsfortegnelse og inid-koder 2020.06.15 - 25/20 Innholdsfortegnelse: Meddelelse til søker/innehaver med ukjent adresse ......................................................................................... 3 Registrerte varemerker ......................................................................................................................................... 4 Internasjonale varemerkeregistreringer ............................................................................................................ 38 Ansvarsmerker .................................................................................................................................................. 137 Avgjørelser etter innsigelser ............................................................................................................................ 138 Avgjørelse fra Klagenemnda ............................................................................................................................ 143 Merkeendringer .................................................................................................................................................. 147 Avgjørelse av krav om administrativ overprøving ........................................................................................
    [Show full text]
  • Integration of Complementary and Alternative Medicine Into Family Practices in Germany: Results of a National Survey
    eCAM Advance Access published March 17, 2009 eCAM 2009;Page 1 of 8 doi:10.1093/ecam/nep019 Original Article Integration of Complementary and Alternative Medicine into Family Practices in Germany: Results of a National Survey Stefanie Joos1, Berthold Musselmann1,2 and Joachim Szecsenyi1 1Department of General Practice and Health Services Research, University Hospital Heidelberg, Voßstrasse 2, 69115 Heidelberg and 2Practice of Family Medicine, Academic Teaching Practice, University of Heidelberg, Hauptstrasse 120, 69168 Wiesloch, Germany More than two-thirds of patients in Germany use complementary and alternative medicine (CAM) provided either by physicians or non-medical practitioners (‘Heilpraktiker’). There is little information about the number of family physicians (FPs) providing CAM. Given the widespread public interest in the use of CAM, this study aimed to ascertain the use of and attitude toward CAM among FPs in Germany. A postal questionnaire developed based on qualitatively derived data was sent to 3000 randomly selected FPs in Germany. A reminder letter including a postcard (containing a single question about CAM use in practice and reasons for non-particpation in the survey) was sent to all FPs who had not returned the questionnaire. Of the 3000 FPs, 1027 (34%) returned the questionnaire and 444 (15%) returned the postcard. Altogether, 886 of the 1471 responding FPs (60%) reported using CAM in their practice. A positive attitude toward CAM was indicated by 503 FPs (55%), a rather negative attitude by 127 FPs (14%). Chirotherapy, relaxation and neural therapy were rated as most beneficial CAM therapies by FPs, whereas neural therapy, phytotherapy and acupuncture were the most commonly used therapies in German family practices.
    [Show full text]
  • Gentle Chiropractic
    Gentle Chiropractic 1 Disclaimer Before you start reading this book I must express to you the importance of seeking medical attention when you have strong pain or after you have had an accident, a fall, or injured your back in any other circumstances. It is important to rule out any fractures, ruptures or other conditions that may be detrimental to proceeding with any of the exercises containing in this book. If you are not sure how to do certain exercises ask a health care practitioner, chiropractor or physiotherapist. The information contained in this E Book is educational in nature. The author has made every reasonable effort to ensure that all information is complete, true, correct, appropriate and accurate. However, the information and advice contained in this E Book is not intended as a substitute for consulting your doctor or health care practitioner regarding any action that may affect your well-being. Gentile Chiropractic is –an E Book to refresh the knowledge of chiropractic practitioners and beginners in learning how to do great gentile chiropractic. It is intended as learning and repeating chiropractic only and not as medical or professional advice. Information contained herein is intended to give you the tools to make better gentile chiropractic. Individual readers must assume responsibility for their own actions, safety and health. The author shall not be liable or responsible for any loss, injury, financial consequences or damage what-so-ever allegedly arising from any information, exercise or other suggestion contained in this E Book. I wish you success Christina Reuter 2 © Copyright Christina Reuter • Chiropractor and Naturopath Otto Fischer Weg 2-1 • D-72766 Reutlingen, Germany • Phone +49 (0) 7 121 - 208 343 • [email protected] • www.christina-reuter.de Welcome to the gentile Chiropractic Hello and welcome to the gentile chiropractic.
    [Show full text]